Stock Research for TNXP

TNXP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TNXP Stock Chart & Research Data

The TNXP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TNXP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TNXP Due diligence Resources & Stock Charts

The TNXP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TNXP Detailed Price Forecast - CNN Money CNN View TNXP Detailed Summary - Google Finance
Yahoo View TNXP Detailed Summary - Yahoo! Finance Zacks View TNXP Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View TNXP Trends & Analysis - Trade-Ideas Barrons View TNXP Major Holders - Barrons
NASDAQ View TNXP Call Transcripts - NASDAQ Seeking View TNXP Breaking News & Analysis - Seeking Alpha
Spotlight View TNXP Annual Report - CompanySpotlight.com OTC Report View TNXP OTC Short Report - OTCShortReport.com
TradeKing View TNXP Fundamentals - TradeKing Charts View TNXP SEC Filings - Bar Chart
WSJ View Historical Prices for TNXP - The WSJ Morningstar View Performance/Total Return for TNXP - Morningstar
MarketWatch View the Analyst Estimates for TNXP - MarketWatch CNBC View the Earnings History for TNXP - CNBC
StockMarketWatch View the TNXP Earnings - StockMarketWatch MacroAxis View TNXP Buy or Sell Recommendations - MacroAxis
Bullish View the TNXP Bullish Patterns - American Bulls Short Pains View TNXP Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View TNXP Stock Mentions - StockTwits PennyStocks View TNXP Stock Mentions - PennyStockTweets
Twitter View TNXP Stock Mentions - Twitter Invest Hub View TNXP Investment Forum News - Investor Hub
Yahoo View TNXP Stock Mentions - Yahoo! Message Board Seeking Alpha View TNXP Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for TNXP - SECform4.com Insider Cow View Insider Transactions for TNXP - Insider Cow
CNBC View TNXP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TNXP - OTC Markets
Yahoo View Insider Transactions for TNXP - Yahoo! Finance NASDAQ View Institutional Holdings for TNXP - NASDAQ


Stock Charts

FinViz View TNXP Stock Insight & Charts - FinViz.com StockCharts View TNXP Investment Charts - StockCharts.com
BarChart View TNXP Stock Overview & Charts - BarChart Trading View View TNXP User Generated Charts - Trading View


Latest Financial News for TNXP

Bullish Insiders Bought More Of These Stocks In June
Posted on Wednesday June 20, 2018

Generally, insiders buying more shares in their own firm sends a bullish signal. A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the marketRead More...


Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
Posted on Thursday May 31, 2018

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®* (cyclobenzaprine HCl sublingual tablets) for the treatment posttraumatic stress disorder (PTSD).  “There are several examples in major psychiatric disorders in which pharmacological treatment of the underlying disorder may decrease suicidal behaviors,” said Gregory Sullivan, M.D., Chief Medical Officer of Tonix.


Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
Posted on Wednesday May 30, 2018

NEW YORK, May 30, 2018-- Tonix Pharmaceuticals Holding Corp., announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present an overview of the Company, focusing ...


Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
Posted on Thursday May 24, 2018

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), announced preliminary results from a Phase 1 pivotal multiple-dose bridging pharmacokinetic study of Tonmya®*, or TNX-102 SL, which is required to support the 505(b)(2) NDA submission for TNX-102 SL, using AMRIX®#  (cyclobenzaprine HCl extended-release [ER]) capsules) as the reference listed drug (RLD).  The design of this study had been previously accepted by the FDA. Specifically, the study compared the plasma levels and the safety profile of TNX-102 SL 5.6 mg (administered as 2 x 2.8 mg tablets) taken sublingually versus the recommended dose of the RLD, AMRIX 30 mg ER capsule, over 20 consecutive days of daily dosing under fasting conditions in healthy subjects aged 18-65 years old.  Tonmya is in Phase 3 development for the bedtime treatment of military-related posttraumatic stress disorder (PTSD) and TNX-102 SL has an effective IND for a Phase 2 efficacy study for the treatment of agitation in Alzheimer’s disease.


Enter a stock symbol to view the stock details.